Schrodinger, Inc. Common Stock

Day range

$28.17 – $30.85

Open

$30.71

Prev close

$30.85

Volume

1.28M

Market cap

$2.32B

Shares out

65.91M

P/E

—

P/S

8.60

P/B

7.67

P/FCF

—

ROE

-19.6%

ROA

-9.7%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 12, 2026

• Business updateNov 4, 2026

  The abstract stated that the Company has an ongoing combination study of SGR-1505 in patients with relapsed/refractory B cell malignancies. The Company has in fact not initiated a combination study of SGR-1505 under its FDA-cleared protocol and, as previously disclosed, is exploring strategic opportunities to continue development of SGR-1505.

• Acquisition completionJun 29, 2026

  In connection with the completion of Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc. ("Ajax"), a company co-founded by Schrödinger, Inc. (the "Company"), the Company received a cash payment of approximately $57 million. The Company is also eligible to receive additional cash payments upon the achievement by Ajax of specified clinical and regulatory milestones.

• Equity compensation grantJun 23, 2026

  The Company's stockholders approved an amendment (the '2026 Plan Amendment') to the Schrödinger, Inc. 2022 Equity Incentive Plan, as amended (the '2022 Equity Incentive Plan'). The 2026 Plan Amendment... increases the number of shares of common stock of the Company available for issuance under the 2022 Equity Incentive Plan by 3,000,000 shares.

• Executive compensation changeJun 8, 2026

  Pursuant to the Separation Agreement, Mr. Aklian is entitled to receive certain payments and benefits in connection with his separation that are substantially comparable to the previously-disclosed benefits he would have received pursuant to the terms of the employment agreement, dated as of May 9, 2025... including: (i) salary continuation payments of his monthly base salary, commencing on the first payroll period occurring on or after the day immediately following the Revocation Period, and continuing for nine months thereafter... (ii) payment on Mr. Aklian's behalf of the portion of his COBRA premiums equal to the premiums that the Company pays on behalf of other active, similarly-situated employees for group health and/or dental insurance coverage, if Mr. Aklian timely elects to receive such coverage, for 12 months following Mr. Aklian's separation from the Company.

• Guidance issuance or updateMay 20, 2026

  The Company reaffirms the full-year and second quarter 2026 financial and operational guidance provided in connection with the Company's first quarter 2026 earnings release, as set forth in the Company's press release dated May 5, 2026.

Days to cover

5.8

Short interest

9.75M

Avg volume

1.67M

As of Oct 30, 2026 · reported to FINRA twice monthly.

• AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights
  positiveGlobeNewswire Inc.· Nov 12, 2026
• Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates
  positiveZacks Investment Research· Nov 4, 2026
• SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
  negativeZacks Investment Research· Nov 3, 2026
• Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?
  positiveZacks Investment Research· Oct 6, 2026
• Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities
  positiveGlobeNewswire Inc.· Oct 5, 2026